Status:
COMPLETED
Role of Inflammasomes in COVID-19 Disease
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
COVID-19 by SARS-CoV-2 Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
As of March 25, 2020, 414,179 cases and 18,440 deaths secondary to Coronavirus 2019 disease (COVID-19) have been reported worldwide. The unfavorable course of the patients is characterized on the immu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age above 18 years old. SARS-CoV-2 infection confirmed by RT PCR or by serology Hospitalised patients with less than 14 days of COVID-19 symptoms. Date of first symptom being defined as to the date of one of the following symptoms : cough, dyspnea, fever above 38 °C, anosmia, dysgeusia or ageusia, chilblain Lupus erythematous Women of fertile age using at least one contraceptive method Health insurance Written informed consent
- Exclusion criteria
- Pregnant or breastfeeding female
- Human immunodeficiency virus infection with CD4 under 200 cell/mm3
- Aplasia
- at-risk patients (minor, patient under judicial protection or tutorship)
Exclusion
Key Trial Info
Start Date :
May 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04385017
Start Date
May 11 2020
End Date
December 30 2022
Last Update
March 22 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ch Cannes, Réanimation
Cannes, Alpes Maritimes, France, 06
2
CHU de nice
Nice, Alpes-Maritimes, France, 06200